AAM All Access Podcast: Lupin’s Vinita Gupta | Association for Accessible Medicines
New Blog - Inflation Rebate Proposal Builds on Bad Policy for Generics

AAM All Access Podcast: Lupin’s Vinita Gupta

AAM’s All Access Podcast lets us all learn from leaders and influential figures in health care. This series of candid, wide-ranging dialogues has given me a deeper appreciation of the dedication and brilliance of the men and women who take on the challenge of making prescription medicines more widely accessible. Only with access to prescription drugs can patients live life to their fullest potential. I very much look forward to continuing these fascinating, educational dialogues and hope you’ll tune in.

Innovation Fuels our Industry

There’s a misconception that brand-name manufacturers are responsible for 100% of pharmaceutical innovation. In my podcast with Vinita Gupta, CEO of AAM member Lupin Ltd., she dispels this myth and offers fascinating insights into running an international enterprise that remains a family business. The company her father started in 1968 to combat tuberculosis now manufactures injectables, inhalers and biosimilars. A commitment to innovation means robust, steady investment in research.

I'm a pharmacist by training, and the opportunities that our industry presents are tremendous. The first thing I say to anyone who wants to be part of our industry is that there are very few industries that let you do so much good while you are building value for yourself and for shareholders. That in itself was a big driver for me. It was a big driver for my family to get into this business. And for anyone who is looking at our industry, you want to look at it long-term. Look at the kind of difference they make, and let that be the purpose. And if that is a purpose, you can have a very, very long enriching career in our industry.

 

 

Dan Leonard, AAM President and CEO

By Dan Leonard, AAM President and CEO
Published on October 18, 2021

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.